Health and Healthcare
624 Articles
Some mergers are very straight-forward, and others are just odd. Now we have an answer over whether or not Amylin…
We are now just about two weeks away from the king of biotech and pharma events in cancer treatments. The 2012…
It is now getting close to the middle of May, and that means one thing for biotech investors. The king…
Diabetes drug maker Amylin Pharmaceuticals Inc. (NASDAQ: AMLN) has hired bankers and lawyers to help the company find a buyer.…
If there was a merger candidate which ever made sense in biotech and pharma it is Amylin Pharmaceuticals, Inc. (NASDAQ: AMLN). …
Amylin Pharmaceuticals Inc. (NASDAQ: AMLN) and Eli Lilly & Co. (NYSE: LLY) are in the news on the diabetes front. …
AuthorDendreon Corp. (NASDAQ: DNDN), maker of prostate cancer drug Provenge, is once again rumored to be a takeover target. As…
By now, most investors know that the large hedge funds are run by billionaires rather than millionaires. What many investors…
Indian drug maker Sun Pharmaceutical Industries Ltd. has received approval from the US Food and Drug Administration to sell its…
All three major indexes opened higher this morning, but the strength didn’t last as the Chicago PMI number failed to…
Drug maker Eli Lilly & Co. reported fourth quarter and full year earnings this morning, and although revenues were higher…
Profits at Eli Lilly & Co. (NYSE: LLY) in 2012 will be sharply lower than analysts had been expecting. The…
Greece will announce its new government today. (Reuters) Inflation in China drops in October. (Reuters) Olympus investment losses may have…
Drug maker Eli Lilly & Co. (NYSE: LLY) reported third-quarter earnings this morning, and the company did a little better…
Once patent protection expires on a prescription drug, the drug’s maker can take a serious beating in revenue and profitability.…
Our top personal finance-related articles today. Your wallet will thank you later.